Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …

Cervical cancer still poses a significant global challenge. Developed countries have
mitigated this challenge by the introduction of structured screening programmes and, more …

Abstract European Guidelines for Quality Assurance in Cervical Cancer Screening have
been initiated in the Europe Against Cancer Programme. The first edition established the …

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines
derived from randomized trials was published in the Cochrane database of Systematic …

Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …

Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …